We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
WuXi PharmaTech Begins Operation of New HPAPI Laboratory
News

WuXi PharmaTech Begins Operation of New HPAPI Laboratory

WuXi PharmaTech Begins Operation of New HPAPI Laboratory
News

WuXi PharmaTech Begins Operation of New HPAPI Laboratory

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "WuXi PharmaTech Begins Operation of New HPAPI Laboratory"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

WuXi PharmaTech (Cayman) Inc. has announced that its manufacturing subsidiary, Syn-The-All Pharmaceutical Co., Ltd. (STA), has begun operation of a high-potency active pharmaceutical ingredient (HPAPI) laboratory in Shanghai, thereby adding HPAPI processing to its portfolio of services.

The lab will support process development and clinical-trial supply of high-potency small molecules at kilogram scale.

"With the increasing use of HPAPIs in drug discovery and development, this new service augments WuXi's ability to provide highly efficient and cost-effective solutions for our partners worldwide," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech.

Advertisement